What are the effects and uses of brigatinib?

Brigatinib is an oral targeted therapy drug used to treat non-small cell lung cancer. It is mainly used to treat EGFR mutation-positive or ALK fusion-positive non-small cell lung cancer. Several clinical studies have shown that the drug can effectively inhibit the growth and spread of cancer cells, thereby controlling the development of lung cancer. Compared with traditional treatments, brigatinib can significantly extend patient survival and slow the progression of the disease. In addition, it has anti-tumor activity and the ability to cross the blood-brain barrier, which provides patients with better quality of life and treatment opportunities.

The initial dose of brigatinib is 90 mg once daily for 7 days. This helps patients gradually adapt to the drug and reduces the occurrence of adverse reactions. As tolerated by the patient, the dose should be adjusted to 180 mg once daily after 7 days. This is the recommended maintenance dose of brigatinib, designed to achieve optimal therapeutic effects.

Brigatinib should be swallowed whole and not crushed or chewed. This ensures that the drug is released slowly in the intestines, thus maintaining stable blood levels. Medications can be taken with or without food, depending on the patient's individual circumstances.

If the medication is suspended for reasons other than adverse reactions (such as missed doses or vomiting after medication)14days or longer, you should press each time before re-administering the medication. 90 mg once daily for 7 days, and then increase to the previously tolerated dose.

During treatment, patients should avoid eating some foods that may affect the effectiveness of the medication, such as grapefruit and grapefruit juice. Also, avoid taking drugs that may interact with brigatinib. In addition, breastfeeding women should stop breastfeeding or choose to discontinue the drug while taking the drug.

References:

https://www.mims.com/hongkong/drug/info/brigatinib?mtype=generic